Nimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies

Article

Abstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approved

Palabras claves:

And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapies

Autores:

Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania Crombet

Fuentes:

scopus